Show simple item record

dc.contributor.authorTRACERx Renal Consortium
dc.contributor.authorLópez Fernández de Villaverde, José Ignacio ORCID
dc.date.accessioned2019-01-09T14:04:47Z
dc.date.available2019-01-09T14:04:47Z
dc.date.issued2018-04-19
dc.identifier.citationCell 173(3) : 611-623 (2018)es_ES
dc.identifier.issn0092-8674
dc.identifier.issn1097-4172
dc.identifier.urihttp://hdl.handle.net/10810/30696
dc.description.abstractClear cell renal cell carcinoma (ccRCC) is characterized by near-universal loss of the short arm of chromosome 3, deleting several tumor suppressor genes. We analyzed whole genomes from 95 biopsies across 33 patients with clear cell renal cell carcinoma. We find hotspots of point mutations in the 50 UTR of TERT, targeting a MYC-MAX-MAD1 repressor associated with telomere lengthening. The most common structural abnormality generates simultaneous 3p loss and 5q gain (36% patients), typically through chromothripsis. This event occurs in childhood or adolescence, generally as the initiating event that precedes emergence of the tumor's most recent common ancestor by years to decades. Similar genomic changes drive inherited ccRCC. Modeling differences in age incidence between inherited and sporadic cancers suggests that the number of cells with 3p loss capable of initiating sporadic tumors is no more than a few hundred. Early development of ccRCC follows well-defined evolutionary trajectories, offering opportunity for early intervention.es_ES
dc.description.sponsorshipWe thank Eleanor Carlyle, Aida Murra, Justine Korteweg, Kim Edmonds, Karla Lingard, Karen O'Meara, Helen Breeze, Lesley Cooper, Linda Shephard, Sharanpreet Lall, Sarah Sarker, and Leonora Conneely for study support. We thank members of the HeritX organization for discussions on prevention of inherited cancers. We thank the patients and their families. The work presented in this manuscript was funded by EU FP7 (project PREDICT ID number 259303) and the Wellcome Trust and Cancer Research UK. S. T. is funded by Cancer Research UK (C50947/A18176). S. T., J. L., and M. G. receive funding from the National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden Hospital and Institute of Cancer Research (A109). J. H. R. F. and A. G. L. were supported by the University of Cambridge, Cancer Research UK (C14303/A17197), and Hutchison Whampoa. K. L. is supported by a UK Medical Research Council Skills Development Fellowship Award. C. S. is funded by Cancer Research UK (TRACERx), the Rosetrees Trust, NovoNordisk Foundation (16584), EU FP7 (projects PREDICT and RESPONSIFY, ID number 259303), the Prostate Cancer Foundation, the Breast Cancer Research Foundation, the European Research Council (THESEUS), and National Institute for Health Research University College London Hospitals Biomedical Research Centre. P. J. C. has a Wellcome Trust Senior Clinical Research Fellowship (WT088340MA).es_ES
dc.language.isoenges_ES
dc.publisherCell Presses_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjecttert promoter mutationses_ES
dc.subjectcopy-numberes_ES
dc.subjectsomatic mutationses_ES
dc.subjectkidney canceres_ES
dc.subjecthTERT genees_ES
dc.subjectC-Myces_ES
dc.subjectcarcinomaes_ES
dc.subjectchromothripsises_ES
dc.subjecttranscriptiones_ES
dc.subjectpatternses_ES
dc.titleTiming the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renales_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holderThis is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).es_ES
dc.rights.holderAtribución 3.0 España*
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S0092867418301648?via%3Dihubes_ES
dc.identifier.doi10.1016/j.cell.2018.02.020
dc.departamentoesEspecialidades médico-quirúrgicases_ES
dc.departamentoeuMedikuntza eta kirurgia espezialitateakes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Except where otherwise noted, this item's license is described as This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).